Sponsor Check › Person
Related person on Form D filings · address states as listed: WA, CA, MI, OH, IL · listed Apr 23, 2012 → Sep 11, 2025
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:58 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
3 of 47 offerings report sales commissions totalling $4,747,501; 1 reports finder's fees totalling $75,000; 1 reports proceeds to related persons totalling $15,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Sep 11, 2025 D File 021-557255 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 17, 2025 D File 021-541158 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 9, 2024 D File 021-521146 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 22, 2022 D/A File 021-393460 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 13, 2022 D File 021-461688 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 13, 2022 D File 021-461697 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 18, 2022 D File 021-438073 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 29, 2021 D File 021-415077 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 13, 2021 D File 021-409959 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 28, 2021 D File 021-404438 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 9, 2021 D File 021-391600 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 21, 2021 D File 021-386939 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 7, 2020 D File 021-372783 | $3,340,002 | $0 | $0 | Cowen and Company BrokerCheck CRD 7616 ↗ Oppenheimer & Co. Inc. BrokerCheck CRD 249 ↗ |
| EDGAR ↗ | Jul 17, 2020 D File 021-371303 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 12, 2020 D File 021-362661 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 17, 2019 D File 021-355633 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 30, 2019 D File 021-331755 | $907,499 | $75,000 | $0 | Piper Jaffray & Co. BrokerCheck CRD 665 ↗ |
| EDGAR ↗ | Apr 10, 2018 D/A File 021-300817 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 9, 2018 D/A File 021-300820 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 28, 2017 D File 021-301902 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 21, 2017 D File 021-301461 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 1, 2017 D File 021-297918 | $0 | $0 | $0 The General Partner receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the Issuer's limited partners (as set forth in the Issuer's partnership agreement). | None listed on this filing |
| EDGAR ↗ | Jul 24, 2017 D File 021-291377 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 21, 2016 D File 021-265425 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 19, 2016 D File 021-263486 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 23, 2016 D/A File 021-250280 | $0 | $0 | $0 Frazier Management, L.L.C. receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the issuer's LPs. | None listed on this filing |
| EDGAR ↗ | Mar 23, 2016 D File 021-259794 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 4, 2016 D File 021-254446 | $500,000 | $0 | $0 | Leerink Partners LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Oct 29, 2015 D File 021-250272 | $0 | $0 | $0 The General Partner receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the Issuer's limited partners (as set forth in the Issuer's partnership agreement). | None listed on this filing |
| EDGAR ↗ | Jul 30, 2015 D File 021-244746 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 24, 2015 D File 021-244446 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 17, 2015 D File 021-234194 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 1, 2014 D File 021-216611 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Oct 10, 2013 D File 021-204370 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 30, 2013 D/A File 021-180706 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive an investment advisory fee payable by the Issuer quarterly in advance. The investment advisory fee will generally be equal to a percentage of commitments as specified in the Issuer's constituent agreement. | None listed on this filing |
| EDGAR ↗ | Aug 16, 2013 D File 021-201465 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 8, 2013 D File 021-196141 | $0 | $0 | $0 (est.) The general partner or an affiliate thereof will receive a management fee payable by FH VII. | None listed on this filing |
| EDGAR ↗ | Feb 26, 2013 D/A File 021-182187 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 23, 2012 D File 021-177068 | $0 | $0 | $15,000 (est.) | None listed on this filing |
| EDGAR ↗ | Dec 21, 2011 D File 021-170477 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 2, 2011 D File 021-169528 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 14, 2011 D File 021-167334 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 7, 2011 D File 021-154949 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 27, 2010 D/A File 021-144409 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 21, 2010 D File 021-149377 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 20, 2010 D File 021-137971 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 14, 2009 D File 021-97987 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Enlaza Therapeutics, Inc. group: Avalon | Director | Sep 11, 2025 | D | $15,000,000 similar: $1,694,259–$16,000,000 | $15,000,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Life Sciences XII, L.P. | Executive Officer Member of the General Partner of the General Partner | Mar 17, 2025 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Enlaza Therapeutics, Inc. group: Avalon | Director | Aug 9, 2024 | D | $110,000,000 similar: $1,694,259–$16,000,000 | $84,000,000 | 16 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Enlaza Therapeutics, Inc. group: Avalon | Director | Nov 22, 2022 | D/A | $61,330,607 similar: $1,694,259–$16,000,000 | $35,299,237 | 10 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Enlaza Therapeutics, Inc. group: Avalon | Director | Oct 13, 2022 | D | $311,977 similar: $1,694,259–$16,000,000 | $0 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Enlaza Therapeutics, Inc. group: Avalon | Director | Oct 13, 2022 | D | Indefinite similar: $1,694,259–$16,000,000 | $0 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Life Sciences XI, L.P. | Executive Officer Member of the General Partner of the General Partner | Mar 18, 2022 | D | $960,000,000 similar: $155,000–$5,250,000 | $960,000,000 | 98 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | ALPINE IMMUNE SCIENCES, INC. group: Alpine Immune Sciences | Director | Sep 29, 2021 | D | $91,003,125 similar: $2,000,000–$19,999,994 | $90,999,934 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Enlaza Therapeutics, Inc. group: Avalon | Director | Aug 13, 2021 | D | Indefinite similar: $1,694,259–$16,000,000 | $0 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Enlaza Therapeutics, Inc. group: Avalon | Director | Jun 28, 2021 | D | Indefinite similar: $1,694,259–$16,000,000 | $0 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Enlaza Therapeutics, Inc. group: Avalon | Director | Mar 25, 2021 | D | $21,273,287 similar: $1,694,259–$16,000,000 | $4,018,630 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Amunix Pharmaceuticals, Inc. | Director | Mar 9, 2021 | D | $116,999,980 similar: $2,000,000–$19,999,994 | $116,999,980 | 28 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Amunix Pharmaceuticals, Inc. | Director | Jan 21, 2021 | D | $743,277 similar: $2,000,000–$19,999,994 | $0 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ALPINE IMMUNE SCIENCES, INC. group: Alpine Immune Sciences | Director | Aug 7, 2020 | D | $82,666,486 similar: $2,000,000–$19,999,994 | $60,000,013 | 25 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Amunix Pharmaceuticals, Inc. | Director | Jul 17, 2020 | D | $2,579,360 similar: $2,000,000–$19,999,994 | $0 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Amunix Pharmaceuticals, Inc. | Director | Mar 12, 2020 | D | $83,590,402 similar: $2,000,000–$19,999,994 | $83,590,402 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Frazier Life Sciences X, L.P. | Executive Officer Member of the General Partner of the General Partner | Dec 17, 2019 | D | $617,050,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | ALPINE IMMUNE SCIENCES, INC. group: Alpine Immune Sciences | Director | Jan 30, 2019 | D | $48,660,651 similar: $2,000,000–$19,999,994 | $25,274,979 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Affiliates IX, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Apr 10, 2018 | D/A | Indefinite similar: $155,000–$5,250,000 | $6,440,000 | 33 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund IX, L.P. group: Frazier Healthcare | Promoter Member of the Issuers' affiliated advisor, Frazier Management, L.L.C. | Apr 9, 2018 | D/A | Indefinite similar: $155,000–$5,250,000 | $775,712,511 | 138 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Millendo Therapeutics, Inc. | Director | Dec 28, 2017 | D | $59,109,960 similar: $1,694,259–$16,000,000 | $50,043,201 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Aptinyx Inc. | Director | Dec 21, 2017 | D | $70,000,000 similar: $1,694,259–$16,000,000 | $70,000,000 | 63 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund IX, L.P. group: Frazier Healthcare | Promoter Member of the Issuers' affiliated advisor, Frazier Management, L.L.C. | Dec 14, 2017 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Affiliates IX, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Dec 14, 2017 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Life Sciences IX, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | Nov 1, 2017 | D | $418,925,000 similar: $155,000–$5,250,000 | $418,925,000 | 55 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Alpine Immune Sciences, Inc. group: Alpine Immune Sciences | Director | Jul 24, 2017 | D | $17,000,004 similar: $2,000,000–$19,999,994 | $17,000,004 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Alpine Immune Sciences, Inc. group: Alpine Immune Sciences | Director | Jun 21, 2016 | D | $47,999,998 similar: $2,000,000–$19,999,994 | $10,333,333 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Aptinyx Inc. | Director | May 19, 2016 | D | $65,000,000 similar: $1,694,259–$16,000,000 | $24,999,999 | 48 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Affiliates VIII, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Mar 23, 2016 | D | $5,000,000 similar: $155,000–$5,250,000 | $5,000,000 | 21 similar: 4–27 | $100,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund VIII, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Mar 23, 2016 | D/A | $519,612,246 similar: $155,000–$5,250,000 | $519,612,246 | 67 similar: 4–27 | $75,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund VIII, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Jan 12, 2016 | D/A | $500,000,000 similar: $155,000–$5,250,000 | $435,000,000 | 62 similar: 4–27 | $75,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Millendo Therapeutics, Inc. | Director | Jan 4, 2016 | D | $70,702,987 similar: $1,694,259–$16,000,000 | $47,697,172 | 21 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund VIII, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Oct 29, 2015 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Life Sciences VIII, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | Oct 29, 2015 | D | $262,000,000 similar: $155,000–$5,250,000 | $262,000,000 | 46 similar: 4–27 | $68,750 similar: $1,000–$100,000 |
| EDGAR ↗ | Laguna Pharmaceuticals, Inc. | Director | Jul 30, 2015 | D | $4,733,337 similar: $1,694,259–$16,000,000 | $4,475,606 | 8 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ANAPTYSBIO INC | Director | Jul 24, 2015 | D | $40,767,277 similar: $2,000,000–$19,999,994 | $40,767,277 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Laguna Pharmaceuticals, Inc. | Director | Feb 17, 2015 | D | $31,851,132 similar: $1,694,259–$16,000,000 | $16,576,124 | 18 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ProNAi Therapeutics Inc | Director | May 1, 2014 | D | $59,500,000 similar: $2,000,000–$19,999,994 | $59,500,000 | 57 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ANAPTYSBIO INC | Director | Oct 10, 2013 | D | $6,250,000 similar: $1,694,259–$16,000,000 | $2,022,117 | 12 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Healthcare VII, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | Sep 30, 2013 | D/A | $400,000,000 similar: $155,000–$5,250,000 | $293,943,299 | 37 similar: 4–27 | $50,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Semnur Pharmaceuticals, Inc. | Director | Aug 16, 2013 | D | $30,000,144 | $6,000,000 | 5 | No minimum reported |
| EDGAR ↗ | Frazier Healthcare VII-A, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | May 8, 2013 | D | $82,500,000 | $82,500,000 | 3 | $1,000,000 |
| EDGAR ↗ | Millendo Therapeutics, Inc. | Director | Feb 26, 2013 | D/A | $16,633,013 | $8,522,872 | 7 | No minimum reported |
| EDGAR ↗ | Millendo Therapeutics, Inc. | Director | Sep 27, 2012 | D/A | $16,633,013 | $3,506,411 | 6 | No minimum reported |
| EDGAR ↗ | Millendo Therapeutics, Inc. | Director | Aug 3, 2012 | D | $16,633,013 | $1,506,411 | 4 | No minimum reported |
| EDGAR ↗ | Frazier Healthcare VII, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | Jul 3, 2012 | D | $400,000,000 | $0 | 0 | $1,000,000 |
| EDGAR ↗ | Millendo Therapeutics, Inc. | Director | Apr 23, 2012 | D | $500,000 | $250,000 | 1 | No minimum reported |
| EDGAR ↗ | PORTOLA PHARMACEUTICALS INC | Director | Dec 21, 2011 | D | $8,999,999 | $8,999,999 | 1 | No minimum reported |
| EDGAR ↗ | PORTOLA PHARMACEUTICALS INC | Director | Dec 2, 2011 | D | $90,000,001 | $88,961,766 | 56 | No minimum reported |
| EDGAR ↗ | ANAPTYSBIO INC | Director | Oct 14, 2011 | D | $21,975,606 | $8,024,394 | 8 | No minimum reported |
| EDGAR ↗ | ANAPTYSBIO INC | Director | Feb 7, 2011 | D | $14,400 | $14,400 | 1 | No minimum reported |
| EDGAR ↗ | CALISTOGA PHARMACEUTICALS INC | Director | Dec 27, 2010 | D/A | $50,000,003 | $24,999,990 | 17 | No minimum reported |
| EDGAR ↗ | ANAPTYSBIO INC | Director | Oct 21, 2010 | D | $9,600 | $9,600 | 1 | No minimum reported |
| EDGAR ↗ | CALISTOGA PHARMACEUTICALS INC | Director | Jul 2, 2010 | D | $40,000,002 | $19,281,219 | 13 | No minimum reported |
| EDGAR ↗ | Incline Therapeutics, Inc. | Director | Jan 20, 2010 | D | $440,000 | $440,000 | 10 | No minimum reported |
| EDGAR ↗ | CALISTOGA PHARMACEUTICALS INC | Executive Officer, Director | May 14, 2009 | D | $31,000,000 | $14,999,999 | 9 | No minimum reported |
| EDGAR ↗ | CALISTOGA PHARMACEUTICALS INC | Executive Officer, Director | Mar 17, 2009 | D | $1,000,000 | $1,000,000 | 1 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); Pooled Investment Fund / 506(b) (83,801 filings); Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it is listed on an issuer this record is also listed on (a second identifier); where it is not, it could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as James Topper. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when James Topper appears on a new Form D, or when a court case or SEC action is matched to them. See plans →